The global DNA and RNA sample preparation market is projected to grow from USD 3,900.0 million in 2025 to approximately USD 7,100.0 million by 2035, recording an absolute increase of USD 3,200.0 million over the forecast period. This translates into a total growth of 82.1%, with the market forecast to expand at a compound annual growth rate (CAGR) of 6.2% between 2025 and 2035.
According to a new report by Fact.MR, this growth is being accelerated by advances in next-generation sequencing (NGS), liquid biopsy development, and the widespread adoption of molecular diagnostics across research, clinical, and industrial laboratories.
Strong Regional Momentum Across Asia-Pacific, North America, and Europe
India is projected to lead the global DNA and RNA sample preparation market with a 9.0% CAGR, followed by China (8.0%), driven by government investments in biotechnology, genomics research, and precision medicine programs.
In North America, the United States is expected to expand at a 5.5% CAGR, supported by rapid adoption of molecular diagnostic tools and growth in cancer genomics. Mexico follows with 5.8% CAGR, fueled by rising clinical testing capacity and healthcare modernization.
Europe remains a key innovation hub, with Germany (5.3%) leading technological adoption in automated nucleic acid extraction systems. Meanwhile, Japan (4.0%) and South Korea (5.0%) continue to strengthen their biomedical research infrastructure to meet growing diagnostic and therapeutic needs.
To access the complete data tables and in-depth insights, request a Discount On The Report here: https://www.factmr.com/connectus/sample?flag=S&rep_id=9323
DNA and RNA Sample Preparation Market Quick Stats
| Metric | Details |
| Market Value (2025) | USD 3.9 billion |
| Forecast Value (2035) | USD 7.1 billion |
| Forecast CAGR (2025–2035) | 6.2% |
| Leading Application | Genomic Research and Diagnostics |
| Key Growth Regions | Asia-Pacific, North America, Europe |
| Key Players | Thermo Fisher Scientific, QIAGEN, Illumina, Roche Diagnostics, Agilent Technologies |
Driving Forces Behind Market Expansion
- Genomic Medicine Acceleration: Increasing adoption of NGS, PCR, and qPCR-based diagnostic techniques is driving demand for high-quality sample preparation reagents and kits.
- Liquid Biopsy and Oncology Research: Expansion of liquid biopsy testing for cancer detection is fueling the need for efficient nucleic acid extraction technologies.
- Automation and High-Throughput Systems: Laboratories are investing in automated extraction platforms to improve accuracy, reproducibility, and throughput.
- R&D Funding and Collaborations: Governments and private institutions are supporting large-scale genomic projects that require robust DNA/RNA processing workflows.
- Emerging Clinical Applications: Growth in infectious disease testing, personalized medicine, and forensic applications continues to boost market demand.
Segment Overview
By Type: DNA extraction kits, RNA extraction kits, and combined nucleic acid prep systems dominate demand, supporting both research and clinical diagnostics.
By Application: Genomic research and molecular diagnostics lead market share, followed by biotechnology, forensic, and pharmaceutical applications.
By End User: Hospitals, diagnostic laboratories, research institutes, and biopharmaceutical companies represent key consumption segments.
Competitive Landscape
Key Players in the DNA and RNA Sample Preparation Market:
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Illumina Inc.
- Roche Diagnostics International Ltd.
- Agilent Technologies Inc.
- Beckman Coulter Life Sciences
- Promega Corporation
- Bio-Rad Laboratories Inc.
- Zymo Research Corporation
- New England Biolabs Inc.
- Takara Bio Inc.
- Norgen Biotek Corp.
- PerkinElmer Inc.
- Analytik Jena AG
- Hamilton Company
These companies are emphasizing automated extraction technologies, high-purity reagent formulations, and AI-assisted data integration to enhance reproducibility and throughput across clinical and research settings. Strategic collaborations and regional expansions are key approaches to maintain leadership in this rapidly evolving sector.
Regional Market Outlook
- Asia-Pacific: Led by India and China, with strong growth in biotechnology infrastructure and public genomics programs.
- North America: The U.S. remains a global leader in clinical diagnostics, NGS-based workflows, and translational research.
- Europe: Germany and the UK are advancing high-throughput genomic pipelines through national healthcare initiatives.
- Latin America: Mexico emerging as a key player with growing molecular diagnostics adoption in public health.
Purchase Full Report for Detailed Insights
For access to full forecasts, regional breakouts, company share analysis, and emerging trend assessments, you can purchase the complete report here: https://www.factmr.com/checkout/9323
Market Outlook: Towards Precision Medicine and Diagnostic Efficiency
The DNA and RNA sample preparation market will continue to gain momentum as precision medicine and genomic sequencing reshape modern healthcare. Increasing R&D collaborations, automation in life sciences labs, and rising demand for point-of-care molecular testing will sustain the market’s robust growth through 2035.
“Sample preparation stands as the foundation of molecular diagnostics and genomic innovation,” said a Fact.MR research analyst. “As sequencing and personalized medicine scale globally, high-quality nucleic acid extraction solutions will be indispensable for advancing healthcare and biotechnology.”
Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us – [email protected]
About Fact.MR
Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.
